Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL925540 | 1.00 | MEN1 (0.44) | MEN1KMT2AALDH1A1ATMSTS | |
| SCHEMBL27809198 | 1.00 | MEN1 (0.44) | MEN1KMT2AALDH1A1ATMSTS | |
| SCHEMBL925281 | 0.96 | ALDH1A1 (0.47) | MEN1KMT2AALDH1A1ATMSTS | |
| SCHEMBL3129810 | 0.96 | ALDH1A1 (0.47) | MEN1KMT2AALDH1A1ATMSTS | |
| SCHEMBL925410 | 0.96 | ALDH1A1 (0.47) | MEN1KMT2AALDH1A1ATMSTS | |
| SCHEMBL925279 | 0.96 | ALDH1A1 (0.47) | MEN1KMT2AALDH1A1ATMSTS | |
| SCHEMBL3129802 | 0.96 | ALDH1A1 (0.47) | MEN1KMT2AALDH1A1ATMSTS | |
| SCHEMBL25355932 | 0.89 | LMNA (0.46) | MEN1KMT2AALDH1A1MAPTHTT | |
| SCHEMBL25997722 | 0.89 | LMNA (0.46) | MEN1KMT2AALDH1A1MAPTHTT | |
| SCHEMBL14453327 | 0.89 | GPR119 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409886-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20160152601-A9 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-06-02 | — | — | US | disclosed |
| EP-2170863-B1 | Pyrimido cyclopentanes useful for the treatment of inflammatory or hyperproliferative diseases | ARRAY BIOPHARMA INC (US) | 2015-09-02 | — | — | EP | disclosed |
| CN-103396409-B | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC | 2015-03-11 | — | — | CN | disclosed |
| US-20140080829-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8618097-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| CN-103396409-A | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC | 2013-11-20 | — | — | CN | disclosed |
| CN-101801955-B | Pyrimidyl cyclopentanes as akt protein kinase inhibitors | ARRAY BIOPHARMA INC | 2013-05-08 | — | — | CN | disclosed |
| US-20110015204-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| EP-2170863-A2 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009006567-A2 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080829-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | MEN1 2182/4885KMT2A 2785/4885ALDH1A1 2573/4885 |
| US-20160152601-A9 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | MEN1 2182/4885KMT2A 2785/4885ALDH1A1 2573/4885 |
| US-20110015204-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | MEN1 2259/4885KMT2A 2688/4885ALDH1A1 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.